Shows / Connected With Latham
Connected With Latham
In each episode of Connected With Latham, we discuss ideas, developments, and trends shaping the global economy.
Episodes
Connected With LathamEpisode 129 – The Growth Rocketship: The Future of the Open Internet With Animoca Brands
Originally founded with a focus on mobile gaming, Animoca Brands has since evolved into one of the most prolific investors in Web3, with a portfolio spanning…
- Connected With Latham
Episode 128 – Drug Pricing and Market Access: Takeaways from the Medicaid Drug Rebate Program Summit 2026
Stakeholders from across the healthcare industry recently convened in Chicago for the Medicaid Drug Rebate Program Summit 2026. In this episode of Connected…
Connected With LathamEpisode 127 – The Growth Rocketship: Deep Research, Bold Bets, and AI — Inside Maverick Capital's $15 Billion Portfolios
Built on a foundation of deep fundamental research and data-driven insights, Maverick Capital manages over US$15 billion across three distinct pillars: Public…
- Connected With Latham
Episode 126 – Shining a Light on the Sunshine Act and Transparency Requirements: A Primer for Life Sciences Companies
The US Physician Payments Sunshine Act requires life sciences companies to publicly report payments, transfers of value, and ownership interests. In the first…
- Connected With Latham
Episode 125 – Drug Pricing and Market Access: The RAPID Pathway
The Centers for Medicare & Medicaid Services (CMS) proposed the Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway to coordinate FDA…
Connected With LathamEpisode 124 – The Growth Rocketship: Brave Capital, Defense Tech, Decisive Technologies!
San Francisco-based venture capital firm Brave Capital partners with companies from pre-seed through growth equity stages, backing transformative technology…
Connected With LathamEpisode 123 – The Growth Rocketship: Hercules Backs Tech, Life Sciences
Hercules Capital provides senior secured loans to high-growth, venture capital-backed companies across technology and life sciences. Since its inception in…
Connected With LathamEpisode 122 – Europe Litigation: Mass Actions at a Global Scale
Europe has entered the collective redress era. The full implementation of the EU Representative Actions Directive, coupled with a surge in litigation funding…
Connected With LathamEpisode 121 – The Growth Rocketship: Inside Boutique Venture With NewView Capital
California-based venture capital and growth firm with more than US$3 billion under management, NewView Capital invests in high-potential technology companies…
Connected With LathamEpisode 120 – The Growth Rocketship: Modernizing Real Estate With Opendoor
Residential real estate platform Opendoor puts homeowners in control by replacing the traditional, passive home-selling process with a streamlined e-commerce…
Connected With LathamEpisode 119 – The Growth Rocketship: How Rakuten Capital Masters Diplomatic Capitalism
The corporate venture capital arm of Rakuten Group, Rakuten Capital invests in innovative startups across fintech, AI, and other high-growth sectors. Since its…
Connected With LathamEpisode 118 – The Growth Rocketship: Axiado Takes Cybersecurity Inside the Rack
Founded in 2020, Axiado deploys hardware-anchored, AI-driven platform security by embedding silicon directly on the rack, protecting AI and cloud…
Connected With LathamEpisode 117 – The Growth Rocketship: Using AI to Accelerate Analog Semiconductor Design With Celera
Celera Semiconductor aims to radically accelerate the development of analog semiconductor chips using AI. Founded in 2018, Celera has raised US$34 million in…
- Connected With Latham
Episode 116 – Drug Pricing and Market Access: CMS Update With Rujul Desai
The Trump administration has advanced many policy initiatives in the drug pricing and market access area, and CMS —the Centers for Medicare & Medicaid Services…
- Connected With Latham
Episode 115 – Drug Pricing and Market Access: Highlights From Recent CMS and AHLA Conferences
Washington, D.C. partner Chris Schott, and associates Danny Machado and Evan Rothkoff, share observations and insights from the recent Centers for Medicare &…
- Connected With Latham
Episode 114 – The Growth Rocketship: Using AI and Human Expertise to Build Tomorrow's Leading Brands With A-Frame
A-Frame Brands identifies emerging signals in culture, consumer behavior, and category white space — then moves fast to bring the right products to shelf. They…
- Connected With Latham
Episode 113 – Helping Holocaust Survivors
Over two decades, more than 350 Latham lawyers have taken on Holocaust reparations matters, helping Holocaust survivors apply for pensions for work performed…
- Connected With Latham
Episode 112 – The Growth Rocketship: Navigating the Institutional Evolution of the Blockchain World With ParaFi
ParaFi Capital is an alternative asset management and technology firm focused on blockchain and digital assets. Founded in 2018, the firm was among the…
- Connected With Latham
Episode 111 – The Growth Rocketship: The Future of Rewards-Based Advertising With Fetch
Founded in 2013, Fetch is a daily rewards destination for consumers and brands, turning everyday actions like shopping, dining out, and playing games into…
- Connected With Latham
Episode 110 – Spotlight on US State Healthcare Transaction Review Laws
States continue to expand their review of healthcare transactions involving private equity, real estate investment trusts, management services organizations…
- Connected With Latham
Episode 109 – Drug Pricing and Market Access: Key Takeaways From 2025 and Outlook for 2026
The drug pricing and market access policy space saw a lot of change in 2025, and the pace is not slowing down. In this episode of Connected With Latham…
- Connected With Latham
Episode 108 – UK FinReg Focus Areas in 2026
In this episode of Connected with Latham, complementing Latham's "10 Key Focus Areas for UK-Regulated Financial Services Firms in 2026" report, London partners…
- Connected With Latham
Episode 107 – Drug Pricing and Market Access: "Think of It as a Loop" — Succeeding in an Evolving Policy Landscape
The pharmaceutical industry has seen major legal and policy changes in recent years, from the Inflation Reduction Act to the Trump administration's aggressive…
- Connected With Latham
Episode 106 – The FDA's New Playbook: Biosimilars, National Priority Vouchers, and the Plausible Mechanism Pathway
Recent FDA actions are reshaping key aspects of drug and biologic development, including the Commissioner's National Priority Voucher program, the "plausible…
- Connected With Latham
Episode 105 – Drug Pricing and Market Access: Government Pricing Assessment Expectations and Benefits
Government pricing assessments are an important tool to help pharmaceutical manufacturers review their government price reporting function. They can also help…
- Connected With Latham
Episode 104 – Drug Pricing and Market Access: Deep Dive on the FDA Commissioner's National Priority Voucher Program Awards
The new FDA Commissioner's National Priority Voucher (CNPV) pilot program promises to reduce recipients' application review times from 10-12 months to just 1-2…
- Connected With Latham
Episode 103 – Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit
Stakeholders from across the healthcare industry — from manufacturers and consultants to outside counsel and government officials — recently convened in…
- Connected With Latham
Episode 102 – EU Data Act: Spotlight on Switching Requirements for Data Processing Services
In this episode of Connected With Latham, London partner Fiona Maclean, Paris partner Jean-Luc Juhan, and London counsel Alain Traill discuss significant new…
- Connected With Latham
Episode 101 – EU Data Act: Implications for Data Privacy and Cybersecurity
In this episode of Connected With Latham, London partner Gail Crawford and Frankfurt partner Tim Wybitul discuss the EU Data Act, and what this means for data…
- Connected With Latham
Episode 100 – The Leeds Reforms: Implications for UK Financial Services
In this episode of Connected with Latham, London partners Rob Moulton and Nicola Higgs discuss the UK government's plans for the financial services sector, and…
- Connected With Latham
Episode 99 – Drug Pricing: Takeaways from the Philadelphia Pricing and Contracting USA Conference
Current developments, such as most favored nation (MFN) pricing, grabbed much of the spotlight when key industry stakeholders met in Philadelphia for the…
- Connected With Latham
Episode 98 – Drug Pricing: Takeaways from the MDMA Annual Meeting
Stakeholders from across the healthcare industry, including members of Congress, the US Food and Drug Administration, and the Center for Medicare and Medicaid…
- Connected With Latham
Episode 97 – Drug Pricing: How the Drug Pricing EO Impacts FDA and Overlaps with Grassley-Led Legislation
The "Lowering Drug Prices by Once Again Putting Americans First" Executive Order addresses various FDA matters, such as importation from Canada and accelerated…
- Connected With Latham
Episode 96 – The Growth Rocketship: Shield AI's Takeoff Shows What's Possible in Defensetech
Founded in 2015, Shield AI uses technology and intelligence systems to protect service members and civilians. The venture-backed unicorn's flagship autonomy…
- Connected With Latham
Episode 95 – Drug Pricing: FDA in the Age of Executive Orders and DOGE
The initial months of the Trump administration have been marked by a flurry of executive orders and significant activity by the Department of Government…
- Connected With Latham
Episode 94 – Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook
Stakeholders from across the healthcare and biopharmaceutical industry recently convened in San Francisco for the annual J.P. Morgan Healthcare Conference. In…
- Connected With Latham
Episode 93 – EU's Digital Operational Resilience Act: What You Should Know and How to Stay Compliant
The deadline for the EU's Digital Operational Resilience Act (DORA) has arrived. This regulation applies to most financial entities operating in the EU market…
- Connected With Latham
Episode 92 – UK FinReg Focus Areas in 2025: Sectoral Trends
In this episode of Connected with Latham, the final of three episodes complementing Latham's "10 Key Focus Areas for UK-Regulated Financial Services Firms in…
- Connected With Latham
Episode 91 – UK FinReg Focus Areas in 2025: Retail Markets
In this episode of Connected with Latham, the second of three episodes complementing Latham's "10 Key Focus Areas for UK-Regulated Financial Services Firms in…
- Connected With Latham
Episode 90 – UK FinReg Focus Areas in 2025: Wholesale Markets
In this episode of Connected with Latham, the first of three episodes complementing Latham's "10 Key Focus Areas for UK-Regulated Financial Services Firms in…
- Connected With Latham
Episode 89 – The Growth Rocketship: How BridgeBio's Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech – Then, Now, and What's Next?
In this episode of Connected With Latham, Haim Zaltzman, Global Vice Chair of Latham's Emerging Companies & Growth Practice, sits down with BridgeBio's…
- Connected With Latham
Episode 88 – Drug Pricing: How Might the Trump Administration Transform FDA Enforcement Activities?
FDA enforcement activities range from administrative actions like conducting establishment inspections and issuing warning letters to judicial enforcement…
- Connected With Latham
Episode 87 – Drug Pricing: What's In the New CMS Medicaid Final Rule?
The Centers for Medicare & Medicaid Services (CMS) recently published its final rule to implement the Medicaid Services Investment and Accountability Act of…
- Connected With Latham
Episode 86 – Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit
Manufacturers, government officials, and other stakeholders recently convened in Chicago for the annual Medicaid Drug Rebate Program Summit. In this episode of…
- Connected With Latham
Episode 85 – Drug Pricing: How The Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry
Recent Supreme Court decisions, such as the opinions in Loper Bright Enterprises v. Raimondo and Relentless v. Department of Commerce that overruled the…
- Connected With Latham
Episode 84 – Pro Bono: Shabir Kabiri's Remarkable Journey from Afghanistan to Asylum in the US
In this episode of Connected with Latham, we explore the remarkable story of Shabir Kabiri, an Afghan refugee who secured asylum in the United States with the…
- Connected With Latham
Episode 83 – Drug Pricing: How Are Payers Responding to the IRA?
The US healthcare landscape is undergoing significant changes as the Centers for Medicare & Medicaid Services (CMS) continues to implement the Inflation…
- Connected With Latham
Episode 82 – Drug Pricing: Takeaways from the New Orleans Pricing and Contracting USA Conference
Current developments grabbed much of the spotlight when key industry stakeholders met in New Orleans for the Pricing and Contracting USA Conference. In this…
- Connected With Latham
Episode 81 – Drug Pricing: A Look Behind the Curtain of the New ASP Reporting Website and Other Data Collection Portals
The Centers for Medicare and Medicaid Services (CMS) recently updated its portal for Average Sales Price (ASP) reporting under Medicare Part B. Data collection…
- Connected With Latham
Episode 80 – Energy & Infrastructure: Why is Energy Tech So Attractive to Venture Capital?
As the energy tech sector continues to mature, venture capital offers an increasingly a viable path to growth as emerging energy tech companies seek to disrupt…
- Connected With Latham
Episode 79 – Pro Bono: Rewilding the Scottish Highlands Through Forest Restoration
Latham's recently released 2023 Pro Bono Annual Review highlights our public service initiatives around the world, including our ongoing relationship with…
- Connected With Latham
Episode 78 – UK FinReg Focus Areas in 2024: ESG
Following an array of ESG-focused regulation and escalating concerns of greenwashing risks in 2023, the year ahead looks to deliver significant industry…
- Connected With Latham
Episode 77 – UK FinReg Focus Areas in 2024: Enforcement Against Individuals
In 2023, the FCA brought more charges for fraud offences against individuals than any other year in the regulator's history, and secured several convictions…
- Connected With Latham
Episode 76 – UK FinReg Focus Areas in 2024: Regulatory Divergence
The UK's announcement of the Edinburgh Reforms in 2022 made clear the government's intention to chart its own course in rulemaking for the UK financial…
- Connected With Latham
Episode 75 – UK FinReg Focus Areas in 2024: Enforcement Against Firms
Two new Joint Executive Directors of Enforcement and Market Oversight appointed by the FCA in 2023 will settle into their roles over the year ahead. Following…
- Connected With Latham
Episode 74 – UK FinReg Focus Areas in 2024: Conduct and Culture
With the UK financial services regulators due to publish Policy Statements to their consultations on diversity and inclusion (D&I) this year, conduct and…
- Connected With Latham
Episode 73 – UK FinReg Focus Areas in 2024: Artificial Intelligence
The coming year looks poised to act as a pivotal junction for the UK financial services regulators in deciding how to approach the regulation of artificial…
- Connected With Latham
Episode 72 – UK FinReg Focus Areas in 2024: The Edinburgh Reforms
Since the announcement of the Edinburgh Reforms in 2022, the UK government has made progress on an assortment of measures spanning financial services…
- Connected With Latham
Episode 71 – Drug Pricing: A Look Ahead at Trends for 2024
The pressure and uncertainty of 2023 will likely continue for drug manufacturers in 2024, with the election cycle bringing added scrutiny. At the federal…
- Connected With Latham
Episode 70 – UK FinReg Focus Areas in 2024: Investment Research
The UK's decision to scrap compulsory research unbundling, following the final recommendations of the Investment Research Review, marked one of the most…